PharmaResearch Co., Ltd. (KOSDAQ: 214450)

Market Cap	2.16T
Revenue (ttm)	296.59B
Net Income (ttm)	90.74B
Shares Out	10.39M
EPS (ttm)	8,276.27
PE Ratio	25.07
Forward PE	17.33
Dividend	950.00 (0.43%)
Ex-Dividend Date	n/a

Volume	122,419
Open	206,500
Previous Close	210,000
Day's Range	205,500 - 221,500
52-Week Range	86,800 - 241,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 403
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214450

Financial Performance

In 2023, PharmaResearch's revenue was 261.01 billion, an increase of 34.02% compared to the previous year's 194.76 billion. Earnings were 76.55 billion, an increase of 88.66%.